EDAP TMS S.A. (EDAP) |
11.39 0.16 (1.42%)
|
03-22 13:05 |
Open: |
11.38 |
Pre. Close: |
11.23 |
High:
|
11.5999 |
Low:
|
11.2 |
Volume:
|
25,558 |
Market Cap:
|
412(M) |
|
|
Technical analysis |
as of: 2023-03-22 12:46:17 PM |
Overall:
|
|
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
Target: |
Six months: 13.88 One year: 14.77 |
Support: |
Support1: 10.64 Support2: 8.86 |
Resistance: |
Resistance1: 11.88 Resistance2: 12.64 |
Pivot: |
11.77  |
Moving Average: |
MA(5): 11.09 MA(20): 11.83 
MA(100): 10.92 MA(250): 8.79  |
MACD: |
MACD(12,26): -0.1 Signal(9): 0  |
Stochastic oscillator: |
%K(14,3): 25.9 %D(3): 17.6  |
RSI: |
RSI(14): 48.7  |
52-week: |
High: 12.64 Low: 6 |
Average Vol(K): |
3-Month: 51 (K) 10-Days: 68 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EDAP ] has closed above bottom band by 37.6%. Bollinger Bands are 63.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
11.26 - 11.33 |
11.33 - 11.4 |
Low:
|
10.63 - 10.72 |
10.72 - 10.81 |
Close:
|
11.08 - 11.23 |
11.23 - 11.37 |
|
Company Description |
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France. |
Headline News |
Tue, 21 Mar 2023 EDAP Presents Positive Results from Non-Inferiority Study ... - GlobeNewswire
Mon, 20 Mar 2023 Ablation Equipment Market Set to Surge with 10.8% CAGR by 2032 ... - GlobeNewswire
Mon, 13 Mar 2023 Ablation Devices Market Demand 2022-2030: Growing Health ... - Digital Journal
Thu, 09 Mar 2023 EDAP to Announce Fourth Quarter and Full-Year 2022 Financial ... - San Mateo Daily Journal
Thu, 09 Mar 2023 High Intensity Focused Ultrasound (HIFU) Market to Surpass US ... - GlobeNewswire
Wed, 22 Feb 2023 Axonics (AXNX): Fundamentals Remain Constructive For Intelligent ... - Seeking Alpha
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Outperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Medical Devices |
Shares Out. |
36 (M) |
Shares Float |
29 (M) |
% Held by Insiders
|
0 (%) |
% Held by Institutions
|
40.1 (%) |
Shares Short
|
33 (K) |
Shares Short P.Month
|
23 (K) |
Stock Financials |
EPS
|
0.1 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
2.2 |
Profit Margin (%)
|
6.6 |
Operating Margin (%)
|
-4.2 |
Return on Assets (ttm)
|
-1.6 |
Return on Equity (ttm)
|
5.8 |
Qtrly Rev. Growth
|
29.7 |
Gross Profit (p.s.)
|
0.5 |
Sales Per Share
|
1.47 |
EBITDA (p.s.)
|
-0.02 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
6 (M) |
Levered Free Cash Flow
|
-1 (M) |
Stock Valuations |
PE Ratio
|
114.75 |
PEG Ratio
|
58.4 |
Price to Book value
|
5.21 |
Price to Sales
|
7.77 |
Price to Cash Flow
|
65.94 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|